Asr Nederland N.v. · EURONEXT:ASRNL
Asr Nederland — Q1 2017 Earnings Presentation
12 slides from Asr Nederland's earnings presentation, May 31, 2017
Slide 1: Strong results in Q1 2017
Strong results in Q1 2017 Chris Figee (CFO) Q1 2017 Trading Update 31 May 2017
Slide 2: Strong financial performance and improvement in earnings quality in Q1 2017
Strong financial performance and improvement in earnings quality in Q1 2017 Operating result Operating ROE Financial results driven by strong operating performance • Results up in terms of quantity and quality: driven by improvement in underwriting results and increase in direct cash investment inco
Slide 3: GWP down due to NIVO portfolio transfer in Q1 2016
GWP down due to NIVO portfolio transfer in Q1 2016 Gross written premiums • In Q1, GWP decreased by 14.9% to 1,626 * 1,383 * € 1,383m. Decline in premiums due to one- off portfolio transfer of NIVO in Q1 2016 (€ 323m) NIVO 323 • In 2017, GWP was positively influenced by € 50m due to a change in meth
Slide 4: Acquisitions and investments drive increase in expenses
Acquisitions and investments drive increase in expenses Operating expenses associated with ordinary activities (excluding provision for restructuring expenses) • Operating expenses were up 6.2% to € 137m compared to € 129m in Q1 2016 • This increase is driven by the additional cost 6.2% base of acqu
Slide 5: All segments drive strong increase in operating result
All segments drive strong increase in operating result Operating result • Non-life segment (+ € 22m): operating (€ million) result significantly better due to higher Q1 2016 Q1 2017 premium income in all product lines, disciplined underwriting combined with a Non-life 32 54 mild winter, absence of l
Slide 6: Non-life segment: combined ratio exceptionally strong
Non-life segment: combined ratio exceptionally strong Combined ratio below 100% for all Non-life product lines Operating result (in € million) Gross written premiums (in € million) • Operating result increased due to the +68.8% +11.1% improvement of the combined ratio within Health 54 934 and P&C; D
Slide 7: Life segment: further performance improvement
Life segment: further performance improvement Operating result • Operating result increased to € 149m, up +23.1% 23.1%. Higher direct investment result and a 149 higher contribution from the realized gains 121 reserve, partly offset by lower results in mortality and cost coverage by decline of indiv
Slide 8: Well-diversified and robust investment portfolio – strong capital position offers opportunity for re-risking
Well-diversified and robust investment portfolio – strong capital position offers opportunity for re-risking Assets (€ billion, fair value) 2016 Q1 2017 Delta • Rise in interest rates in Q1 impact fair value of Fixed income 26.0 24.8 -1.2 fixed-income securities Equities 2.2 2.5 0.3 • Re-allocation
Slide 9: Solid Solvency II ratio at Q1 2017
Solid Solvency II ratio at Q1 2017 Solvency II • Solvency II ratio (standard formula) at 188% (FY2016: 189%), absorbing additional 6,539 allocation to market risk (~ 5%-pts) and the share buyback (~ 2%-pts), compensated by organic capital creation, business and market developments • Eligible own fun
Slide 10: Strong financial performance and improvement in earnings quality in Q1 2017
Strong financial performance and improvement in earnings quality in Q1 2017 Operating result Operating ROE Financial results driven by strong operating performance • Results up in terms of quantity and quality: driven by improvement in underwriting results and increase in direct cash investment inco
Slide 11: Contact details
Contact details Investor Relations ir@asr.nl Michel Hülters T +31 (0)6 15 49 95 69 Barth Scholten T +31 (0)6 30 44 15 71 11
Slide 12: Disclaimer
Disclaimer Cautionary note regarding forward-looking statements currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. Some of the statements contained herein are not based on historical facts, including, without limitation, certain statements mad